1-6 of 6
Benga Kazeem
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy

Free
Attaya Suvannasankha, Benga Kazeem, Paul MacLeod, Ewa Dlotko, Natalie Boytsov, Yevgeniy Samyshkin, Simon McNamara, Molly Purser, Sandhya Sapra, Martin Kaiser
Journal: Blood
Blood (2025) 146 (Supplement 1): 4041.
https://doi.org/10.1182/blood-2025-4041
Published: 2025
Journal Articles

Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7

Free
Sagar Lonial, Craig Cole, Angely Loubert, Laurine Bunod, Manal M'Hari, Pralay Mukhopadhyay, Sandhya Sapra, Molly Purser, Jacqueline Nielsen, Benga Kazeem, Farrah Pompilus, Paul Richardson
Journal: Blood
Blood (2025) 146 (Supplement 1): 4029.
https://doi.org/10.1182/blood-2025-4029
Published: 2025
Journal Articles

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis

Free
Joshua Richter, Meral Beksac, Alessandro Corso, Ollie Schofield, Dani Olivier, Leanne Cooper, Owen Harrison, Jacopo Bitetti, Benga Kazeem, Alex Bates, Natalie Boytsov, Simon McNamara, Adil Merchant, Connor Lloyd, Christina-Jane Crossman-Morgan, Nicholas Meader, Molly Purser, Nick Ballew
Journal: Blood
Blood (2025) 146 (Supplement 1): 7567.
https://doi.org/10.1182/blood-2025-7567
Published: 2025
Journal Articles

An exploratory analysis of health-related quality of life measures with belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in dreamm-8

Free
Paul Richardson, Craig Cole, Angely Loubert, Laurine Bunod, Manal M'Hari, Pralay Mukhopadhyay, Sandhya Sapra, Molly Purser, Benga Kazeem, Farrah Pompilus, Sagar Lonial
Journal: Blood
Blood (2025) 146 (Supplement 1): 2284.
https://doi.org/10.1182/blood-2025-2284
Published: 2025
Journal Articles

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

Free
María-Victoria Mateos, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, Phoebe Joy Ho, Roman Hajek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Martinez, Anna Sureda Balarí, Jie Ma, Yinjiao Ma, Maureen Nichols, Jorge Mouro, Zeyad Khalaf, Hena Baig, Benga Kazeem, Nick Pirooz, Sybil Varghese, Joe Lee, Lydia Eccersley, Vania Hungria
Journal: Blood
Blood (2025) 146 (Supplement 1): 2265.
https://doi.org/10.1182/blood-2025-2265
Published: 2025
Journal Articles

Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Free
Vania Hungria, Marek Hus, Pawel Robak, Vera Zherebtsova, Ana Carolina de Almeida Ribas, Marcelo Pitombeira de Lacerda, Kihyun Kim, Sebastian Grosicki, Irwindeep Sandhu, Christopher Ward, Astrid McKeown, Hena Baig, Jie Ma, Benjamin Lariviere, Benga Kazeem, Lydia Eccersley, Sumita Roy-Ghanta, Joanna Opalinska, Maria Victoria Mateos
Journal: Blood
Blood (2024) 144 (Supplement 1): 3359.
https://doi.org/10.1182/blood-2024-201543
Published: 2024